Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia CEO increased shareholding in the company in January
Aiforia Technologies Plc Press Release February 4, 2025 at 5.30 p.m. EET
Aiforia’s CEO Jukka Tapaninen increased his shareholding in the company in January 2025. On January 7, 2025, the company published a management transaction notification regarding Tapaninen's acquisition of 3,298 shares. On February 4, 2025, Tapaninen's total shareholding in Aiforia is 621,798 shares, representing a 2.15% of total amount of shares in the company.
On February 4, 2025, an error was discovered in the share register, according to which Tapaninen's ownership had decreased by 400,000 shares during January. The company is investigating the matter with the share register of Euroclear Finland Ltd and the book-entry account operator, and aims to correct the error and update the share information as soon as possible.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com